Gastric sleeve surgery centres vary widely in quality, regulation, and aftercare provision — making the choice of provider one of the most consequential decisions a patient will face. Sleeve gastrectomy, which permanently removes approximately 75–80% of the stomach, is a highly effective intervention for obesity and related conditions such as type 2 diabetes and hypertension. This guide covers how the procedure works, how to identify a regulated UK centre, NHS and private referral pathways, what to expect at each stage of your care, and the clinical risks and long-term follow-up requirements you need to understand before proceeding.

What Is Gastric Sleeve Surgery and How Does It Work?

Sleeve gastrectomy removes 75–80% of the stomach laparoscopically, restricting food intake and reducing ghrelin levels. It is irreversible and carries a perioperative mortality of approximately 0.1–0.3% in UK high-volume centres.

Gastric sleeve surgery, formally known as sleeve gastrectomy, is a type of bariatric (weight-loss) surgery in which approximately 75–80% of the stomach is surgically removed, leaving a narrow, sleeve-shaped pouch roughly the size of a banana. This significantly reduces the stomach's capacity, limiting the amount of food a person can consume at any one time. It is important to note that sleeve gastrectomy is irreversible — the removed portion of the stomach cannot be restored.

The procedure works through two primary mechanisms:

• Restriction: The smaller stomach volume means patients feel full much sooner after eating, naturally reducing caloric intake.

• Hormonal changes: Removing a large portion of the stomach also reduces levels of ghrelin — often called the 'hunger hormone' — which can help decrease appetite over time.

Unlike gastric bypass surgery, sleeve gastrectomy does not reroute the digestive tract, making it a less anatomically complex procedure. It is performed laparoscopically (keyhole surgery) under general anaesthesia, typically taking between 60 and 90 minutes. Most patients are discharged within one to two days.

Sleeve gastrectomy is considered an effective intervention for people living with obesity, particularly where weight-related health conditions such as type 2 diabetes, hypertension, or obstructive sleep apnoea are present, as outlined in NICE Clinical Guideline CG189. Clinical evidence demonstrates meaningful weight loss following the procedure; on average, many patients lose 50–70% of their excess body weight within the first 18 to 24 months, though outcomes vary considerably between individuals and depend significantly on adherence to dietary changes and ongoing MDT support.

As with all surgical procedures, sleeve gastrectomy carries a small but important perioperative mortality risk, estimated at approximately 0.1–0.3% in UK high-volume centres. This should be discussed as part of the informed consent process. Surgery is a tool — long-term success depends heavily on sustained lifestyle changes and ongoing clinical support.

Choosing a Regulated Gastric Sleeve Surgery Centre in the UK

UK bariatric centres must hold a satisfactory CQC inspection rating and comply with NHS England specialised commissioning requirements. Patients should verify surgical volume, MDT provision, and outcomes data via the National Bariatric Surgery Register.

Selecting the right gastric sleeve surgery centre is one of the most important decisions a patient will make. In the UK, bariatric surgery centres should be regulated and meet standards set by the relevant national body: the Care Quality Commission (CQC) in England, Healthcare Improvement Scotland (HIS), Healthcare Inspectorate Wales (HIW), or the Regulation and Quality Improvement Authority (RQIA) in Northern Ireland. Centres should also comply with NHS England's specialised commissioning service specifications for bariatric surgery and take account of recommendations from the Getting It Right First Time (GIRFT) programme, which aims to improve the quality and consistency of bariatric services across the NHS.

When evaluating a centre, patients and referring clinicians should consider the following:

• Regulatory status: Verify that the centre holds a current, satisfactory inspection rating from the CQC (or equivalent devolved body) and complies with NHS England specialised commissioning requirements.

• Multidisciplinary team (MDT): High-quality centres offer input from bariatric surgeons, specialist dietitians, clinical psychologists, specialist nurses, and physicians.

• Surgical volume: Evidence from GIRFT and other sources indicates that higher-volume centres are associated with better outcomes and lower complication rates.

• Aftercare provision: Robust long-term follow-up, including nutritional monitoring and psychological support, is essential.

• Outcomes data: Patients and clinicians can review centre and surgeon outcomes through the National Bariatric Surgery Register (NBSR). For private providers, the Private Healthcare Information Network (PHIN) publishes comparable safety and outcomes data.

The operating surgeon should be listed on the General Medical Council (GMC) Specialist Register with a recognised subspecialty in bariatric or upper gastrointestinal surgery.

Patients are encouraged to ask prospective centres about their complication rates, revision surgery rates, and the specific aftercare packages included. Transparency in these areas is a hallmark of a reputable, patient-centred service.

NHS vs Private Centres: Eligibility and Referral Pathways

NHS eligibility follows NICE CG189, typically requiring a BMI of 40 kg/m² or above, or 35–39.9 kg/m² with a significant comorbidity, plus completion of a structured weight management programme. Private centres offer faster access but costs typically range from £8,000 to £15,000.

Access to gastric sleeve surgery in the UK differs considerably depending on whether a patient pursues treatment through the NHS or the independent (private) sector. Understanding both pathways helps patients make informed decisions.

NHS eligibility is guided by NICE Clinical Guideline CG189 (Obesity: identification, assessment and management). To be considered, patients typically must:

• Have a BMI of 40 kg/m² or above, or a BMI of 35–39.9 kg/m² with a significant obesity-related comorbidity (e.g., type 2 diabetes, hypertension)

• Have a BMI of 30–34.9 kg/m² with recent-onset type 2 diabetes, for whom bariatric surgery may also be considered — and expedited assessment is recommended for those with a BMI of 35 kg/m² or above and recent-onset type 2 diabetes, in line with NICE NG28 (Type 2 diabetes in adults: management)

• Have completed a structured weight management programme

• Be fit for surgery and general anaesthesia

• Demonstrate commitment to long-term dietary and lifestyle changes

Clinicians should also be aware that NICE acknowledges ethnicity-related differences in metabolic risk; for people of Asian family origin, lower BMI thresholds may be appropriate, and thresholds should be individualised accordingly.

Referrals are usually made by a GP to a specialist Tier 3 or Tier 4 weight management service. Waiting times on the NHS can be lengthy, and availability varies significantly by Integrated Care Board (ICB) area. Patients are encouraged to check their local ICB's criteria and referral routes. The GP also plays an important role in coordinating pre-referral medical optimisation, including management of diabetes, obstructive sleep apnoea, and other comorbidities.

Private centres offer a more accessible route for patients who do not meet NHS criteria or who wish to avoid waiting lists. Costs for sleeve gastrectomy in the UK private sector typically range from £8,000 to £15,000, depending on the centre and package. Patients should ensure that any private provider follows NICE-aligned clinical pathways and offers equivalent pre- and post-operative care, and should review outcomes data via PHIN before proceeding.

Regardless of the route chosen, patients should discuss their options with their GP, who can provide guidance, coordinate investigations, and ensure appropriate medical optimisation before surgery.

What to Expect Before, During and After Your Procedure

Pre-operative preparation includes medical assessment, OSA screening, smoking cessation, and a liver-reducing diet. Post-operatively, lifelong supplementation and a staged return to solid food are required, and urgent medical attention should be sought for severe abdominal pain, fever, or chest pain.

A well-structured bariatric pathway involves careful preparation, a clearly defined surgical process, and a structured recovery plan. Understanding each stage helps patients engage actively with their care.

Before surgery, patients typically undergo:

• Comprehensive medical assessment including blood tests, ECG, and respiratory evaluation

• Obstructive sleep apnoea (OSA) screening — a formal sleep study may be arranged if OSA is suspected, and CPAP therapy should be optimised before surgery if already in use

• Smoking cessation — patients are strongly advised to stop smoking ideally at least eight weeks before surgery to reduce anaesthetic and wound-healing risks; support is available through NHS Stop Smoking services

• Alcohol assessment — patients should be advised to reduce alcohol intake before surgery and to avoid alcohol in the post-operative period

• Nutritional assessment and dietetic counselling

• Psychological evaluation to assess readiness and identify any underlying mental health concerns

• A pre-operative liver-reducing diet (usually a high-protein, low-carbohydrate diet for two to four weeks) to shrink the liver and reduce surgical risk

During the procedure, sleeve gastrectomy is performed under general anaesthesia using laparoscopic techniques. The surgeon makes several small incisions in the abdomen, inserts a camera and instruments, and removes the majority of the stomach using surgical staples. The procedure generally lasts 60–90 minutes.

After surgery, the immediate recovery period involves:

• A liquid diet for the first two to four weeks, progressing gradually to puréed, soft, and then solid foods

• Pain management, typically with oral analgesia

• Early mobilisation to reduce the risk of deep vein thrombosis (DVT)

• Proton pump inhibitors (PPIs) to protect the gastric sleeve lining — typically prescribed for four to eight weeks post-operatively; longer-term use may be recommended for patients with gastro-oesophageal reflux or increased ulcer risk, as directed by the surgical team

• Lifelong vitamin and mineral supplementation, in line with BOMSS guidance — this typically includes a complete multivitamin and mineral supplement, iron, calcium with vitamin D, and vitamin B12 (oral or intramuscular, as clinically indicated). Stopping supplements without medical advice can lead to serious deficiencies

• Contraception and pregnancy planning — women of childbearing age should use effective contraception and are advised to avoid pregnancy for at least 12–18 months after surgery, when weight loss is most rapid and nutritional status may be less stable. Preconception planning should involve the bariatric team and obstetric services

Most patients return to light activities within two to four weeks and to full activity within six to eight weeks.

Seek urgent medical attention — call 999 or go to A&E — if you experience any of the following after surgery:

• Severe or worsening abdominal pain

• Persistent vomiting or inability to keep fluids down

• Fever or signs of infection

• Chest pain or difficulty breathing

• Rapid or irregular heartbeat

• Unilateral leg swelling, redness, or pain (which may indicate DVT)

For any other concerns during recovery, contact your surgical team promptly.

Risks, Complications and Clinical Guidelines for Sleeve Gastrectomy

Short-term risks include staple line leak (1–3%), bleeding, infection, and VTE; long-term risks include GORD, nutritional deficiencies, gallstones, and weight regain. Informed consent must cover all risks in line with NICE CG189 and GMC guidance.

As with all surgical procedures, sleeve gastrectomy carries both short- and long-term risks. Patients should receive thorough informed consent from their surgical team prior to proceeding, in line with NICE CG189 and GMC guidance on consent.

Perioperative mortality is estimated at approximately 0.1–0.3% in UK high-volume centres, and this risk should be discussed openly as part of the consent process.

Short-term risks include:

• Staple line leak — a rare but serious complication occurring in approximately 1–3% of cases, requiring urgent intervention

• Bleeding at the staple line or from surrounding vessels

• Infection, including wound infection or intra-abdominal abscess

• Venous thromboembolism (VTE), including DVT and pulmonary embolism — risk is mitigated with prophylactic anticoagulation and early mobilisation

• Anaesthetic complications, particularly relevant in patients with significant comorbidities

Long-term risks include:

• Gastro-oesophageal reflux disease (GORD) — sleeve gastrectomy can worsen or precipitate reflux in some patients. Pre-existing GORD or a hiatus hernia is an important consideration when choosing between sleeve and bypass procedures, and should be discussed with the surgical team

• Nutritional deficiencies, particularly of vitamin B12, iron, folate, vitamin D, and calcium

• Gallstone formation — rapid weight loss after surgery increases the risk of gallstones. Some centres monitor for biliary symptoms post-operatively; patients should report right upper abdominal pain or jaundice to their clinical team

• Weight regain, particularly if dietary and behavioural changes are not maintained

• Stricture of the sleeve, causing difficulty swallowing or persistent vomiting

NICE CG189 recommends that bariatric surgery should only be performed in centres with a fully integrated MDT and that all patients should be offered long-term follow-up. NICE also advises that surgery should be considered as part of a broader weight management strategy, not as a standalone intervention. Shared decision-making is central to this process — patients should have a clear understanding of both the benefits and the limitations of the procedure before giving consent.

If you experience side effects from any medicines prescribed as part of your care (such as PPIs or nutritional supplements), or have concerns about a medical device used during your procedure, you can report these via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Long-Term Support and Follow-Up Care at UK Bariatric Centres

NICE CG189 and BOMSS require structured long-term follow-up including annual blood tests, dietetic and psychological support, and bone health monitoring. Lifelong vitamin and mineral supplementation is mandatory, and NSAIDs should be avoided due to increased ulceration risk.

Long-term follow-up is not optional — it is a clinical necessity following sleeve gastrectomy. NICE CG189 and BOMSS both emphasise that ongoing support is integral to achieving and maintaining the health benefits of bariatric surgery.

Reputable gastric sleeve surgery centres in the UK provide structured follow-up that typically includes:

• Regular clinic appointments at one month, three months, six months, and annually thereafter

• Annual blood tests aligned with BOMSS postoperative monitoring guidance, including: full blood count (FBC), ferritin, folate, vitamin B12, urea and electrolytes (U&Es), liver function tests (LFTs), adjusted calcium, vitamin D, parathyroid hormone (PTH), and magnesium. Zinc, copper, selenium, and thiamine should be checked if clinically indicated (e.g., symptoms of deficiency or high-risk patients). Thyroid function tests should be performed where clinically indicated rather than routinely for all patients

• Bone health monitoring — vitamin D and PTH should be monitored regularly; a DXA scan to assess bone density should be considered in patients with risk factors for metabolic bone disease

• Dietetic support to guide dietary progression, address nutritional concerns, and support healthy eating habits long term

• Psychological support, which is particularly important for patients who experience emotional eating, body image concerns, or mental health challenges post-operatively

• GP involvement, with shared care letters ensuring the patient's primary care team is informed and engaged

Patients should be aware that lifelong vitamin and mineral supplementation is required following sleeve gastrectomy, in line with BOMSS guidance. Stopping supplements without medical advice can lead to serious deficiencies, including anaemia and metabolic bone disease.

Alcohol and medication cautions: Alcohol should be consumed with caution after bariatric surgery, as absorption and tolerance may change significantly. Non-steroidal anti-inflammatory drugs (NSAIDs) should be avoided where possible due to the increased risk of gastric ulceration; patients should seek prescriber advice before taking NSAIDs or over-the-counter pain relief.

Weight regain is a recognised challenge for some patients in the years following surgery. Centres should offer access to additional support — including behavioural therapy, dietetic review, or consideration of revision surgery — if significant weight regain occurs. Patients are encouraged to maintain contact with their bariatric team even if they feel well, as some complications and deficiencies can develop without obvious symptoms.

Choosing a centre that prioritises long-term care, not just the surgical episode itself, is one of the most important factors in achieving lasting health outcomes after gastric sleeve surgery.

Frequently Asked Questions